Biotechnology

Moderna

Moderna President Stephen Hoge Sells 53,336 Shares at $48.4 and Exercises Options

Moderna Stock Surges 13% Amid Hantavirus Outbreak; Analysts Cite Limited Commercialization Potential

Arbutus Biopharma reports Q1 2026 net income of $169.7 million

Moderna Recognized for mRNA Achievements and Approved for Flu and COVID Combo Vaccine

Bernstein Analyst Reiterates Neutral Rating on Moderna

Moderna Presents mRNA-4359 Cancer Antigen Therapy Study Results

Moderna's mRNA-1010 Phase 3 Trial Shows 26.6% Relative Efficacy in Adults over 50 Against Standard Flu Vaccine; FDA Expected to Make Decision

Moderna begins developing hantavirus vaccine

Moderna Experiences Elevated Call Option Activity as Directors and President Sell Shares

Moderna Announces mRNA-1010 Influenza Vaccine Phase 3 Clinical Trial Results

Sigma Planning Corp. made a new investment of about $907,000 in Moderna

UBS Raises Moderna Target Price to $45 and Maintains Neutral Rating

Moderna released FY2026 Q1 earnings on May 1 During-Market EST, actual revenue USD 389 M (forecast USD 236.36 M), actual EPS USD -3.4 (forecast USD -3.8799)

Moderna's Q2 Revenue Forecast Falls Short of Analyst Estimates, Stock Price Dips

Moderna Engages in Smooth Consultation with FDA on Influenza Vaccine

Moderna Reports Exceeding Q1 Revenue and Predicts Future Growth

M&T Bank Significantly Increased Holdings in Moderna

Moderna to Release FY2026 Q1 Earnings on May 1 During Market Hours (EST), Forecast Revenue USD 248.24M, EPS USD -2.667

Moderna Launches Phase 3 Study for Experimental mRNA Pandemic Flu Vaccine Candidate

Moderna Launches mRNA Influenza Vaccine Phase Trial

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Moderna, Inc. (MRNA.US) Q1 2026 Earnings Conference Call

Moderna, Inc. (MRNA.US) Q4 2025 Earnings Conference Call

Moderna, Inc. (MRNA.US) Q3 2025 Earnings Conference Call

Moderna, Inc. (MRNA.US) Fourth Quarter 2024 Earnings Conference Call

Moderna, Inc. (MRNA.US) Q3 2024 Earnings Conference Call

MRNA

Moderna (MRNA) is gaining attention after its mRNA 1010 flu vaccine showed superior results compared to standard vaccines for adults over 50. Despite a recent share price pullback, analysts suggest the stock is undervalued at $49.04 compared to a fair value of $175. The company has a strong pipeline and low debt, but ongoing losses and valuation risks remain. Investors are weighing the potential for growth against current market sentiment.

Simplywall

Assessing Moderna (MRNA) Valuation After Flu Vaccine Data And Hantavirus Program Interest

Moderna Inc shares rose 13% amid concerns over a localized Hantavirus outbreak on the MV Hondius, which resulted in three deaths. Bernstein Global Research downplayed pandemic risks, maintaining a Market-Perform rating with a $45 price target, indicating a potential 17% downside. They noted the localized nature of the outbreak makes a global crisis unlikely. Moderna is positioned to develop Hantavirus countermeasures, but any commercial returns are expected to come from government funding rather than mass consumer sales.

Investing

AllianceBernstein

Hantavirus: Is there a risk of another pandemic?

CRMG

Salesforce (NYSE:CRM) stock rose 3.7% to $173.77, driven by positive sentiment from a $72 million U.S. Air Force contract and a partnership with Moderna. Despite this, Citi and other analysts have lowered their price targets, reflecting concerns over weak enterprise software spending. The stock maintains a 'Moderate Buy' rating with an average price target of $278.82. Salesforce reported strong quarterly earnings, exceeding estimates, and recently increased its dividend to $0.44 per share.

Market Beat

Salesforce

Leverage Shares 2X Long CRM Daily ETF

Citigroup

Jefferies Financial

Piper Sandler Cos

KeyCorp

Wells Fargo

NASDAQ Composite Index

CITIGROUP INC 6.250 NON CUM SER II PFD WI

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Salesforce (NYSE:CRM) Stock Price Up 3.7%  - Still a Buy?

ABUS

IBBQ

LABU

ARKG

Arbutus Biopharma (ABUS) reported Q1 2026 revenue of $179.1M and net income of $169.7M, primarily due to a $178.7M license payment from the Genevant/Moderna settlement. The adjusted loss was $0.05 per share, slightly worse than the expected $0.03. Revenue decreased by 40% year-over-year. The stock has declined approximately 4.2% this quarter and 10.4% year-to-date, with a 12-month price target of $5.00.

TradingView

Arbutus Pharma

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

VanEck Biotech ETF

iShares US Pharma

ALPS Medical Breakthrough

VG Health

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

Key facts: ABUS Q1 $179.1M revenue; $169.7M net, $0.05 adj loss

Moderna, Inc. has been ranked no. 1 on TIME's 2026 list of the World's Most Impactful Companies, recognizing its pioneering work in mRNA technology. CEO Stéphane Bancel emphasized the company's commitment to innovative medicines and pandemic preparedness. In 2026, Moderna received European approval for its flu plus COVID combination vaccine, mCOMBRIAX®. The company continues to expand its partnerships and invest in its mRNA Access program, which supports research against emerging diseases. The ranking is based on a science-based methodology evaluating companies' net-positive contributions across various dimensions.

MorningStar

NASDAQ-100

ACCESS Newswire

Moderna Recognized by TIME as One of the World's Most Impactful Companies

Moderna's stock surged 36.08% from $43.69 to $59.45 in early May, driven by a hantavirus outbreak on the MV Hondius, according to BeInCrypto. The rally was fueled by three catalysts: a 260% year-over-year revenue increase to $389 million in Q1 2026, a collaboration with the US Army Medical Research Institute of Infectious Diseases on a hantavirus vaccine, and the publication of Phase 3 mRNA-1010 flu data in the New England Journal of Medicine. Moderna's stock is now consolidating near $54.05, forming a cup-and-handle pattern, with a potential breakout above $60.96.

CoinLive

Hantavirus Outbreak Boosts Moderna Stock by 36%

Bernstein analyst Courtney Breen has reaffirmed a Hold rating on Moderna (MRNA) with a price target of $45.00, while the shares closed at $52.88. Breen, who focuses on the Healthcare sector, has an average return of 16.0% and an 82.00% success rate. Additionally, Jefferies analyst Andrew Tsai also issued a Hold rating on Moderna, while Piper Sandler reiterated a Buy rating on May 8.

Tip Ranks

Eli Lilly

Merck

Bernstein Reaffirms Their Hold Rating on Moderna (MRNA)

QDEL

The recent Hantavirus outbreak aboard a cruise ship has shifted market focus to biotech and healthcare stocks. Three companies poised to benefit are Moderna Inc (MRNA), which has a Hantavirus vaccine program, QuidelOrtho (QDEL), which could see increased demand for respiratory diagnostics, and 3M Inc (MMM), a major supplier of protective equipment. Analysts predict significant stock price increases for all three as global health responses intensify.

Invezz

QuidelOrtho

Hantavirus outbreak: these 3 stocks are poised to rip higher

Moderna(MRNA.US)